Member Profile

Dr. Brian Feldman
MD, MSc, FRCPC

Dr. Brian Feldman is Professor of Pediatrics, the Institute of Medicine, and the Institute of Health Policy Management & Evaluation at the University of Toronto. He is Division Head of Rheumatology at The Hospital for Sick Children. Dr. Feldman graduated from the University of Western Ontario (MD, 1985) and he did further graduate training in clinical epidemiology at the University of Toronto (MSc, 1994). He interned at the Mount Sinai Hospital in Toronto and went on to do a core pediatric residency at the Children’s Hospital of Eastern Ontario. Dr. Feldman returned to Toronto to be an associate chief resident at The Hospital for Sick Children. He stayed on there to complete a fellowship in pediatric rheumatology.

Dr. Feldman’s main focus has been in clinical research in the field of childhood rheumatic disease. Recognizing the challenges involved in the study of rare disease Dr. Feldman has worked to improve the tools available to assist in this research. He has worked at developing and refining outcome measurement tools for use in clinical trials and in outcome studies. He has developed innovative methodologies for the study of new therapies (e.g. the Randomized Placebo Phase Design) and refined and tested powerful existing methods (e.g. Bayesian meta-analysis of n-of-1 randomized trials). Dr. Feldman has made contributions to the understanding of the prognosis and treatment of juvenile dermatomyositis, the cost-effective prevention of arthropathy in severe hemophilia, the course and outcome of systemic-onset juvenile idiopathic arthritis and juvenile SLE, and the role of fitness and exercise in childhood chronic diseases including arthritis and fibromyalgia.

Dr. Feldman’s research, by its nature, is collaborative. As such he is a member of the Pediatric Rheumatology Collaborative Study Group, the Canadian Alliance of Pediatric Rheumatology Investigators, the International Myositis Assessment Criteria study group, and other collaborative organizations. He was one of the founding members of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was the head of the protocol evaluation subcommittee and chair of the Juvenile Dermatomyositis subcommittee. Dr. Feldman is also a former member of the Steering Committee, member Physical Therapy Expert Working Group, and former Outcome Measures Expert Working Group of the International Prophylaxis Study Group.

Key Publications
  1. World Federation of Hemophilia 2012 World Congress, Paris, France, July 10, 2012, Plenary Session. Implementing musculoskeletal outcome assessments in clinical practice.
  2. World Federation of Hemophilia 2012 World Congress, Paris. France. July 10. 2012. Session Chair: Outcome assessment and limitations.
  3. World Federation of Hemophilia 2012 World Congress, Paris, France, July 10, 2012. Quality of life assessment.
  4. World Federation of Hemophilia 2013 World Congress, Seefeld. Austria, March 15, 2013. Musculoskeletal Outcome Assessment.
  5. CHPS and other snacks: Which one to choose when shopping the ‘aisle’ of prophylaxis? Winnipeg MB. May 25, 2013. CHPS: A 15-year Journey: Key Findings & Lessons Learned.

 

Current Positions/Chairs:

  • Division Head
    Department of Rheumatology at The Hospital for Sick Children
  • Professor of Pediatrics
    The Institute of Medicine, Institute of Health Policy Management & Evaluation at the University of Toronto
  • Senior Scientist
    Child Health Evaluative Sciences, The Hospital for Sick Children
  • Founding Member
    Childhood Arthritis and Rheumatology Research Alliance (CARRA), and was the head of the protocol evaluation subcommittee and chair of the Juvenile Dermatomyositis subcommittee
  • Chair
    Ho Family Chair in Autoimmune Research

Key Institutions

  • The Hospital for Sick Children
    Department of Paediatrics, Division of Rheumatology, and The Research Institute
    Toronto , Canada
  • The University of Toronto
    Departments of Pediatrics and Institute of Health Policy Management & Evaluation in the Dalla Lana School of Public Health
    Toronto , Canada

Research Activities

  • Canadian Hemophilia Dose Escalation Primary Prophylaxis (CHPS-3) Observational Extension Study. Feldman UM, Ulanchette V, Rivard GE, lsraels 5, Chan A, Lillicrap D, Willan A. Einarson T. Babyn P, Doria A, Wintle R: Bayer Inc. (583,671.71 2010-2012) P1
  • The Hemophilia Joint Health Score v2.1 Validation in Adult Patients Study: (HJHS - VAPS) A multi-centre international study. St-Louis J, Feldman BM: International Prophylaxis Study Group ( 88,735.19 12/2014 – 06/2016 )
  • Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World: The Sao Paulo-Toronto Hemophilia Study. Feldman BM, Blanchette V: Baxter Healthcare Corporation (219,637.94 02/2010-02/2013) P1
  • Pilot Study of Once-A-Day Prophylaxis for Youth and Young Adults with Severe Hemophila. Feldman BM, Rivard G, Carcao M, St-Louis J, Teitel J, Pulleneyegum E, Blanchette V: Bayer Partnership Fund ($250,000 11/2007 - 0W2010) P1
  • Models of Care Catalyst Grant. Feldman BM, Levy D. Arthritis Society ($54.780 10/2013 - 09/2014, extended to 09/2015)
  • Effects of Creatine Supplementation on Muscle Pathophysiology in Children with Dermatomyositis, Stephens S. Feldman BM. Wells GD. Tien I. Schuize A. Rare Disease Foundation and the BC Childrerisliospital Foundation (BCCNF) (3,500 2012-2013)P1
  • The Effect of creatine supplementation on muscle function in childhood myositis, Feldman BM, Stephens S, Wells GD, Tien I, Schulze A, Schneiderman J. The Myositis Association (100,000 2014-2016) PI
  • Cost-effectiveness of escalating dose factor VIII prophylaxis in severe haemophilia A. Blanchette V (Principal Investigator), Feldman B: Bayer Canada/Canadian Red Cross Society Blood Services Research and Development Programme ($473,000 1996 - 2001)
  • An open dose escalating factor VIII prophylaxis study assessing the safety efficacy and cost-effectiveness in young patients with severe haemophilia A. Blanchette V (Principal Investigator), Feldman B: Bayer Canada ($585,076.52 2003-2006)
  • An open dose escalating factor VIII prophylaxis study assessing the safety efficacy and cost-effectiveness in young patients with severe haemophilia A Extension. Blanchette V (Principal Investigator), Feldman B (Co-Principal Investigator): Bayer Canada ($
  • An open dose escalating factor VIII prophylaxis study assessing the safety efficacy and cost-effectiveness in young patients with severe haemophilia A (Canadian haemophilia primary prophylaxis observational extension study). Blanchette V (Principal Invest
  • An open dose escalating factor VIII prophylaxis study assessing the safety efficacy and cost-effectiveness in young patients with severe haemophilia A (Canadian haemophilia primary prophylaxis observational extension study and pharmacokinetic substudy).

Research Interests

  • Clinical research in the field of childhood rheumatic disease
  • Developing and refining outcome measurement tools for use in clinical trials and outcome studies in rare disease groups

Publications

April 17, 2012

Hemophilia Prophylaxis: How can we justify the costs?

Authors
Feldman BM, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Hoots K, Mantovani L, Willan A, and Schramm W.
Citation
Haemophilia 2012 Sept; 18 (5): 680-684.
January 28, 2011

Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the Hemophilia Joint Health Score (HJHS).

Authors
Feldman BM, Funk S, Bergstrom B-M, Zourikian N, Hilliard P, van der Net J, Engelbert RHH, Petrini P, van den Berg M , Manco-Johnson M, Rivard GE, Abad A, and Blanchette VS.
Citation
Arthritis Care & Research 2011 Feb; 63 (2):223-30.
July 1, 2008

A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG).

Authors
Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.
Citation
Haemophilia 2008, 14 (S2), 133 # 24 PO 17.
July 1, 2008

The Haemophilia Joint Health Score (HJHS) international validation study.

Authors
Feldman B M, Funk S, Hilliard P, van der Net J, Zourikian N, Bergstrom B-M, Engelbert RHH, Abad A, Petrini P, Manco-Johnson M, and on behalf of the International Prophylaxis Study Group.
Citation
Haemophilia 2008, 14 (S2), 83 # 12 PO 85.
June 1, 2008

PT HJHS Pre-Congress Workshop

The XXVII International Congress of the World Federation of Hemophillia (June 1-5, 2008 – Istanbul, Turkey)
Authors
Hilliard, P, Funk S, Zourikian N, Bergstrom B-M, van der Net JJ, and Feldman BM
Citation
June 1, 2008

Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG)

The XXVIII World Federation of Hemophilia Congress (June 1-5, 2008 – Istanbul, Turkey) Invited symposium as part of the scientific program of the WFH Congress (Chair: Dr. Victor Blanchette). Dr. Victor Blanchette, Overview of the International Prophylaxis Study Group, Ms. Sharon Funk and Dr. Brian Feldman, Hemophilia Joint Health Score. Dr. Andrea Doria and Dr. Bjorn Lundin, Role of MRI for detection of early arthropathy: A proposed new International MRI Score.
Authors
Feldman BM, Funk S, Lundin B, Doria AS, Blanchette V.
Citation
June 1, 2008

A review of health economic studies in hemophilia prophylaxis: a collaboration of the economics expert working group of the International Prophylaxis Study Group (IPSG)

The XXVIII World Federation of Hemophillia Congress (June 1-5, 2008 – Istanbul, Turkey).
Authors
Carcao M, Fischer K, Steen-Carlsson K, Schramm W, Feldman B, and Berger K.
Citation
June 1, 2008

The Haemophilia Joint Health Score (HJHS) international validation study

The XXVIII World Federation of Hemophillia Congress (June 1-5, 2008 – Istanbul, Turkey).
Authors
Feldman B M, Funk S, Hilliard P, van der Net J, Zourikian N, Bergstrom B-M, Engelbert RHH, Abad A, Petrini P, Manco-Johnson M, and on behalf of the International Prophylaxis Study Group.
Citation
May 16, 2008

Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG).

Authors
Feldman BM, Funk S, Lundin B, Doria AS, Ljung R, and Blanchette V.
Citation
Haemophilia 2008, 14 (Suppl. 3), 162-169.
November 13, 2007

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of the International Prophylaxis Study Group.

Authors
Nicholson A, Berger K, Bohn R, Carcao M, Fischer K, Gringeri A, Mantovani L, Hoots K,, Schramm W, van Hout BA, Willan AR, and Feldman BM.
Citation
Haemophilia 2008 Jan; 14 (1):127 -132.
September 10, 2007

The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) Symposium.

Authors
Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W and Blanchette VS.
Citation
Haemophilia 2007 Nov; 13 (6): 745-749.
August 15, 2006

Hemophilia joint health score reliability study.

Authors
Hilliard P, Funk S, Zourikian N, Bergstrom B-M, Bradley CS, McLimont M, Manco-Johnson M, Petrini P, van den Berg M, and Feldman BM.
Citation
Haemophilia 2006 Sept; 12: 518 – 525.
August 15, 2006

Reliability study of the Hemophilia Joint Health Score.

Authors
Hilliard P, Funk S, Zourikian N, Bergstrom B-M, Bradley CS, McLimont M, Manco-Johnson M, Petrini P, van den Berg M, and Feldman BM.
Citation
Haemophilia 2004 Oct; 10 (S3): 79 # 16 S 03.
January 21, 2005

Proceedings of the International Haemophilia Prophylaxis Study Group Meeting November 2003, Montreal, PQ, Canada.

Authors
Feldman BM, Babyn P, Doria AS, Heijnen L, Jacobson J, Kilcoyne R, Lundin B, Manco-Johnson M, McLimont M, Petrini P, Pettersson H, and Blanchette VS on behalf of the IPSG.
Citation
Haemophilia 2005 Jan; 11: 58 – 63.
October 17, 2004

Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions

The XXVI World Federation of Hemophillia Congress (October 17-21, 2004 - Bangkok, Thailand). Invited symposium as part of the scientific program of the WFH Congress (Chairs: Dr. Victor. Blanchette and Dr. Marilyn Manco-Johnson). Dr. Victor Blanchette, Opening remarks. Dr. Bjorn Lundin, X-ray.MRI Scoring Systems: Overview. Dr. Andrea Doria, Compatible Scales for progressive and additive MRI of hemophilic arthropathy. Dr. Pia Petrini, Physical Therapy Scale Overview. Dr. Brian Feldman, Reliability of the Hemophilia Joint Health Score (HJHS).
Authors
Doria AS, Feldman BM, Lundin B, and Blanchette VS on behalf of the IPSG
Citation
October 17, 2004

Reliability study of the Hemophilia Joint Health Score

The XXVI World Federation of Hemophillia Congress (October 17-21, 2004 - Bangkok, Thailand).
Authors
Hilliard P, Funk S, Zourikian N, Bergstrom B-M, Bradley CS, McLimont M, Manco-Johnson M, Petrini P, van den Berg M, and Feldman BM.
Citation
October 8, 2004

Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions.

Authors
Manco-Johnson MJ, Pettersson H, Petrini P, Babyn PS, Bergstrom B-M, Bradley CS , Doria AS, Feldman BM, Funk S, Hilliard P, Kilcoyne R, Lundin B, Nuss R, Rivard G, Schoenmakers MA, van den berg M, Wiedel J, Zourikian N, and Blanchette VS.
Citation
Haemophilia 2004 Oct; 10 (S4):88 – 93.